---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-21-000018"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2021-07-29T23:59:59+00:00"
generated_at: "2026-06-30T01:19:21.112012+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Gilead Q2 2021 revenue $6.2B (+21% YoY); GAAP EPS $1.21, non-GAAP EPS $1.87; raises Veklury guidance

## Summary
- Total Q2 revenue $6.2B (+21% YoY); product sales ex-Veklury $5.3B (+5%).
- GAAP diluted EPS $1.21 (vs. loss of $2.66); non-GAAP diluted EPS $1.87 (+68%).
- Veklury sales $829M; HIV sales $3.9B (-2%); Biktarvy up 24%; HCV up 23%.
- FY2021 guidance: product sales $24.4-25.0B; Veklury $2.7-3.1B (prev $2.0-3.0B); non-GAAP EPS $6.90-7.25.
- Quarterly dividend $0.71 payable Sep 29, record Sep 15; pipeline updates include lenacapavir NDA filing.

## SEC filing metadata
- accession: 0000882095-21-000018
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2021-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209521000018/0000882095-21-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209521000018/gild-20210729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-21-000018
- JSON: https://secwatch.observer/filing/0000882095-21-000018.json
- Plain text: https://secwatch.observer/filing/0000882095-21-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.